eFFECTOR Therapeutics

eFFECTOR Therapeutics is pioneering a new class of small molecule drugs that act by selectively regulating translation, also known as protein synthesis. The company unites breakthrough insights into the mechanisms of translational control with a proven approach to product invention. eFFECTOR Therapeutics expects this fusion to yield important new therapies for cancer and other serious diseases.

<< Portfolio